Daratumumab 达雷木单抗; Anti-Human CD38, Human Antibody|cas:945721-28-8|西域试剂

Daratumumab 达雷木单抗; Anti-Human CD38, Human Antibody,98.70%

产品编号：Bellancom-P9915| CAS NO：945721-28-8

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P9915		￥1600.00	杭州北京（现货）
Bellancom-P9915		￥5600.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Daratumumab 达雷木单抗; Anti-Human CD38, Human Antibody

产品介绍

Daratumumab (Anti-Human CD38) 是首创的特异性抗 CD38 单克隆抗体 (IgG1)。Daratumumab 具有抗多发性骨髓瘤(MM) 的作用。Daratumumab 损伤了 MM 细胞的粘附，从而增加了 MM 对蛋白酶体抑制的敏感性。

生物活性

Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.

体外研究

Daratumumab (Anti-Human CD38) induces potent Ab-dependent cellular cytotoxicity in CD38-expressing lymphoma- and MM-derived cell lines.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Daratumumab (i.p.; 0.5 mg/kg; 14 d after challenge with Daudi-luc cells) inhibits outgrowth of CD38-expressing tumor cells in mouse xenograft tumor models.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	8- to 10-wk-old C.B-17 SCID mice (luciferase-expressing Daudi cells)
Dosage:	0.5 mg/kg
Administration:	I.p.; 14 day after challenge with Daudi-luc cells
Result:	Effectively inhibited tumor growth compared with control-treated animals in which tumor grew rapidly and therefore required euthanasia on day 35. On day 28 and day 35, tumor size in Daratumumab-treated animals was significantly different from the control.

体内研究

Daratumumab (i.p.; 0.5 mg/kg; 14 d after challenge with Daudi-luc cells) inhibits outgrowth of CD38-expressing tumor cells in mouse xenograft tumor models.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	8- to 10-wk-old C.B-17 SCID mice (luciferase-expressing Daudi cells)
Dosage:	0.5 mg/kg
Administration:	I.p.; 14 day after challenge with Daudi-luc cells
Result:	Effectively inhibited tumor growth compared with control-treated animals in which tumor grew rapidly and therefore required euthanasia on day 35. On day 28 and day 35, tumor size in Daratumumab-treated animals was significantly different from the control.